Researchers now know that MS starts way earlier than the clinical onset, creating the real possibility that MS could one day be controlled.

Study findings suggest using the drug PF-06409577 to restore CDX2 in colon cancers could cut risk of recurrence and death by up to 50%.

Genomics unveils Mystra at ASHG 2025—an AI genetics platform to accelerate drug discovery and clinical validation using large-scale genetic data.

In this GEN interview, Nobel Laureate David Baker, PhD, emphasizes that designing proteins from scratch is reality and unpacks what's needed for AI to transform medicine.

BioAgilytix now operates 355,000-square-feet of laboratory facilities, including 24,000-square-feet dedicated to LC/MS.

Researchers say findings help to bridge the structure of the genome to its function in managing how genes are turned on and off.

As developers of gene editing therapies and other genetic medicines get set to report third quarter earnings in coming days, analysts and especially investors will keep their eyes on whether the ...

The peptide lab is designed to produce a range of molecules, including linear peptides, cyclic peptides, and peptide-drug conjugates.

Using CRISPR-based genetic engineering, the team further identified mutations in viral genes that prevent activation, ...

Serbia’s BIO4 Campus reflects the convergence biosciences, AI, and IT to power innovation and global collaboration.

In this GEN webinar, a distinguished panel of experts discuss next-generation expression systems, optimized screening methods, and integrated development strategies that are enabling higher-performing ...

Despite economic uncertainty, the CEOs of life science and biotech companies are making artificial intelligence a top ...